Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Table 1
Parameters of patients with T2DM and NAFLD at baseline.
Group 1 ()
Group 2 ()
Group 3 ()
value
Baseline
24 weeks
Baseline
24 weeks
Baseline
24 weeks
Age (yr)
53.46 ± 11.25
54.64 ± 9.71
54.17 ± 10.42
0.85
Gender (M/F)
31/19
29/21
25/21
0.75
Weight (kg)
76.43 ± 10.16
71.27 ± 10.50
75.93 ± 11.17
73.28 ± 10.82
75.92 ± 11.54
66.59 ± 10.28
0.97
Height (m)
1.65 ± 0.08
1.66 ± 0.07
1.65 ± 0.08
0.63
BMI (kg/m2)
28.17 ± 2.60
26.34 ± 3.52
27.53 ± 2.81
26.59 ± 2.95
27.96 ± 2.97
24.56 ± 3.03
0.52
ALT (U/L)
86.75 ± 27.59
63.04 ± 26.80
90.79 ± 28.13
40.45 ± 16.30
91.64 ± 28.61
32.23 ± 16.18
0.66
AST (U/L)
67.28 ± 34.68
53.38 ± 29.81
69.38 ± 35.79
32.06 ± 10.41
69.60 ± 36.00
25.91 ± 13.82
0.94
GGT (U/L)
88.96 ± 43.02
59.53 ± 32.38
90.29 ± 37.12
43.32 ± 22.63
93.27 ± 34.98
33.57 ± 16.07
0.86
CB (umol/L)
5.14 ± 3.10
3.07 ± 1.80
6.52 ± 4.18
3.60 ± 2.36
6.45 ± 3.40
4.09 ± 3.12
0.10
TB (umol/L)
15.77 ± 6.29
9.81 ± 4.87
15.31 ± 6.79
12.16 ± 4.83
17.25 ± 7.72
11.04 ± 4.92
0.37
TG (mmol/L)
2.97 ± 1.21
1.82 ± 0.96
3.07 ± 1.04
1.80 ± 0.78
3.24 ± 1.21
1.33 ± 0.57
0.52
TC (mmol/L)
6.57 ± 1.71
5.22 ± 1.22
6.39 ± 1.73
5.44 ± 1.19
6.62 ± 1.71
4.38 ± 1.47
0.79
HDL (mmol/L)
0.91 ± 0.30
1.14 ± 0.39
0.94 ± 0.28
1.09 ± 0.39
0.95 ± 0.28
1.32 ± 0.35
0.80
LDL (mmol/L)
4.09 ± 1.34
3.59 ± 1.50
3.95 ± 1.02
3.66 ± 1.50
4.15 ± 0.87
2.80 ± 1.35
0.68
SF (µg/L)
216.85 ± 81.06
160.18 ± 66.23
223.02 ± 78.37
177.47 ± 67.09
227.50 ± 87.31
130.19 ± 63.63
0.82
HbA1c (%)
8.82 ± 1.79
6.84 ± 1.42
8.70 ± 1.74
8.20 ± 1.90
9.09 ± 1.80
6.23 ± 0.93
0.55
FBG (mmol/L)
9.10 ± 3.02
7.23 ± 1.92
9.27 ± 2.35
8.51 ± 2.22
9.35 ± 2.41
6.38 ± 1.29
0.89
FINS (mU/L)
14.63 ± 3.89
12.04 ± 4.28
15.06 ± 3.71
13.96 ± 3.94
14.84 ± 4.58
9.87 ± 3.39
0.87
HOMA-IR
6.02 ± 3.04
4.16 ± 2.46
6.34 ± 2.51
5.50 ± 2.65
6.56 ± 3.55
2.93 ± 1.51
0.68
CT ratio
0.62 ± 0.16
0.74 ± 0.20
0.62 ± 0.16
0.73 ± 0.21
0.64 ± 0.15
0.89 ± 0.21
0.81
Fibroscan
10.83 ± 2.91
8.54 ± 2.73
11.08 ± 2.33
8.68 ± 2.46
9.94 ± 2.47
6.72 ± 2.02
0.08
values were calculated by one-factor analysis of variance or the Wilcoxon signed rank test for intergroup comparisons at baseline. Group 1: metformin-diet-exercise-treated group; group 2: DGEC-diet-exercise-treated group; group 3: drugs combination-diet-exercise-treated group.
